Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation
Abstract
PURPOSE The likelihood of finding a human leukocyte antigen (HLA)–matched unrelated donor (MUD) for hematopoietic cell transplantation can be predicted using a donor search prognosis score. Patients without a MUD may use alternative donors (haploidentical related, mismatched unrelated, or umbilical cord blood). METHODS This multicenter biological assignment trial was conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1702). Eligibility criteria were broad to mirror clinical practice. The primary end point was 2-year survival from evaluability and compared between those Very Likely (>90%) and Very Unlikely (<10%) to find a MUD. All other patients, Less Likely to find a MUD, were enrolled in an observational arm. Transplant outcomes were compared for all three groups. RESULTS A total of 1,751 evaluable patients at 47 centers were Very Likely (54.7%), Less Likely (29.5%), and Very Unlikely (15.8%) to identify a MUD. Survival did not differ in univariate (hazard ratio [HR], 1.00 [95% CI, 0.82 to 1.21]; P = .98) or multivariate (HR, 1.07 [95% CI, 0.86 to 1.33]; P = .56) analyses between the Very Unlikely and Very Likely groups, measured through 2 years from the beginning of a search for a MUD or alternative donor. Of the transplanted patients (n = 1,179), MUD was used for 94% of the Very Likely, 38% of Less Likely, and 9% of Very Unlikely patients. Multivariate analyses showed no differences in relapse, treatment-related mortality, disease-free survival, and acute and chronic graft-versus-host diseases for the three search prognosis groups after transplantation. CONCLUSION Using a donor search prognosis strategy to prioritize an alternative donor for patients Very Unlikely to find a MUD resulted in survival and transplant outcomes that were not statistically different compared with those Very Likely to find a MUD.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (25)
Stephanie J. Lee
Brent Logan
2CIBMTR/Medical College of Wisconsin, Milwaukee, United States
Mary M. Horowitz
2Division of Hematology and Oncology, Department of Medicine, Center for International Blood and Marrow Transplant Research/Medical College of Wisconsin, Milwaukee, WI
Jason G. Dehn
NMDP, Minneapolis, MN
Joseph Pidala
1H. Lee Moffitt Cancer and Research Institute, Tampa, United States
Michael R. Grunwald
12Levine Cancer Institute, Atrium Health, Charlotte, NC
Peter Westervelt
11Massachusetts General Hospital, Boston, United States
Nosha Farhadfar
6Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, United States
William J. Hogan
Division of Hematology, Mayo Clinic Rochester, Rochester, MN
Asad Bashey
9BMT Program at Northside Hospital, Atlanta, United States
Brandon Hayes-Lattin
1Oregon Health and Science University, Portland, United States
LaQuisa Hill
9Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX
Claudio Brunstein
1Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Cleveland, United States
Sally Arai
Samer A. Srour
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Heather Symons
25Johns Hopkins Hospital, Division of Pediatric Oncology, Department of Oncology, Baltimore, United States
Joseph Uberti
1Karmanos Cancer Institute, Detroit, United States
Sumithira Vasu
29Department of Internal Medicine, The Ohio State University, Columbus, OH
Iskra Pusic
6Washington University in St. Louis School of Medicine, St. Louis, United States
Mark Juckett
8University of Minnesota, Minneapolis, United States
Eric Leifer
Naya He
Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
Steven Devine
24National Marrow Donor Program, Minneapolis, United States
Bronwen E. Shaw
CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
Stefan O. Ciurea
University of California-Irvine, Irvine, CA